Fatty Liver Treatment After Your Scan

You have an ultrasound for discomfort, a routine check or an unrelated concern. The report mentions a fatty liver. You may feel well, rarely drink alcohol and have never thought of yourself as someone with liver disease. The first question is often simple: how serious is this, and what should I do next?

• Fat accumulation, liver inflammation and fibrosis are different findings.
• A scan suggesting fat does not automatically mean cirrhosis.
• Feeling well does not rule out liver risk.

This guide follows the clinical decisions after a scan. It differs from our general liver wellness article: a documented liver finding needs assessment, not only general wellbeing advice.

Ultrasound may suggest that the liver contains excess fat, often described using terms such as increased echogenicity. It can also identify some structural changes. However, a routine ultrasound does not reliably distinguish simple fat accumulation from inflammation or determine the full extent of scarring.

• Older sources use NAFLD and NASH; current terminology often uses MASLD and MASH.
• Review alcohol, medicines, supplements and previous liver problems.
• Ask about findings beyond fat, such as nodularity or a focal lesion.

Ask for clarification if the report mentions nodularity, portal hypertension, a focal lesion or another finding beyond fat. Those details may change the assessment pathway. Keep a copy of the original report rather than relying on a brief verbal summary.

The key question is whether there may be clinically important fibrosis. Assessment usually starts with medical history, examination and blood results. Liver enzymes are useful, but normal values do not reliably exclude significant disease. A single result should not be treated as a complete liver health score.

• A clinician may use FIB-4 to assess risk using age and selected blood results.
• Age, acute illness and clinical context affect interpretation.
• Elastography or specialist review may be appropriate when risk is uncertain or raised.
• A biopsy is not necessary for everyone.

Also discuss other possible causes of abnormal liver tests, including viral hepatitis where relevant. The correct pathway depends on the whole picture, not simply the word fatty in an ultrasound report. Asking what has been excluded is as important as asking what has been found.

Evidence-based fatty liver treatment addresses the underlying metabolic context and the level of liver risk. Diabetes, blood pressure and abnormal lipids matter because cardiovascular health and liver health are connected. Management may involve your primary physician, a dietitian and, where appropriate, a liver specialist.

• Address diabetes, blood pressure and abnormal cholesterol alongside liver risk.
• If appropriate, aim for gradual weight reduction rather than crash diets.
• Choose sustainable dietary changes and physical activity suited to your health.
• Exercise can be useful even when weight changes slowly.

People without excess weight can still have metabolic fatty liver and need assessment. Do not dismiss the finding because your weight appears normal. Equally, recommendations should not reduce the condition to body size or blame: genetics, medications and metabolic factors can all influence the picture.

There is no single medicine appropriate for every person with fat seen on a scan. Treatment decisions depend on whether there is MASH, the degree of fibrosis, other conditions and the therapies approved in the country where care is delivered. Eligibility needs to be assessed rather than assumed.

• Medicines for diabetes or weight management are chosen according to overall health.
• Liver-directed medicines are for defined eligible groups, not every scan finding.
• Do not stop prescribed medicines without advice.
• Include alcohol and natural supplements in the review.

Alcohol advice should be individualised, especially when fibrosis or other liver disease is present. Be honest about amounts and patterns so that care is based on accurate information. A supplement labelled natural can also carry risks and should be included in the review.

The liver already performs complex processing and elimination functions. A product described as cleansing does not show that it reduces fibrosis or improves clinically meaningful outcomes. Feeling more energetic after an infusion is not evidence that a liver condition has been treated.

• IV nutrients and supplements do not replace metabolic or specialist care.
• Correcting a documented deficiency is different from treating liver fibrosis.
• Cell-based approaches are not established treatment for an incidental fatty liver finding.

If a provider recommends an additional treatment, ask which diagnosis it addresses, what evidence supports that indication, how outcomes will be measured and what standard care must continue. Our cell-therapy safety guide can help frame questions, but cannot establish liver-treatment benefit.

Leave with a clear explanation of the likely cause, whether fibrosis assessment is needed, the immediate management steps and the timing of review. Bring previous results where possible so that changes can be interpreted over time rather than as isolated numbers.

• Clarify the likely cause and whether fibrosis testing is needed.
• Agree on nutrition, activity, metabolic monitoring and medication review.
• Ask when results should be reviewed and what would prompt referral.

If considering care abroad, share reports first and ensure that follow-up is available at home. MRC Healthcare can discuss medical assessment and suitable next steps, but an enquiry does not establish eligibility for regenerative treatment. A useful outcome is an accurate diagnosis and a coordinated plan that protects both liver and overall health.